Accès gratuit
Numéro
Med Sci (Paris)
Volume 28, Numéro 12, Décembre 2012
Page(s) 1069 - 1071
Section Nouvelles
DOI http://dx.doi.org/10.1051/medsci/20122812017
Publié en ligne 21 décembre 2012
  1. Nielsen M, Thomsen JL, Primdahl S, et al. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 1987 ; 56 : 814–819. [CrossRef] [PubMed]
  2. Akslen LA, Naumov GN. Tumor dormancy: from basic mechanisms to clinical practice. Apmis 2008 ; 116 : 545–547. [CrossRef] [PubMed]
  3. Quesnel B. «Je te tiens, tu me tiens». Dormance tumorale : un équilibre instable? Med Sci (Paris) 2008 ; 24 : 575–576. [CrossRef] [EDP Sciences] [PubMed]
  4. Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991 ; 22 : 339–347. [PubMed]
  5. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989 ; 339 : 58–61. [CrossRef] [PubMed]
  6. Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol 2009 ; 19 : 329–337. [CrossRef] [PubMed]
  7. Folkman J, Kalluri R. Cancer without disease. Nature 2004 ; 427 : 787. [CrossRef] [PubMed]
  8. Naumov GN, Bender E, Zurakowski D, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006 ; 98 : 316–325. [CrossRef] [PubMed]
  9. Straume O, Shimamura T, Lampa MJ, et al. Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proc Natl Acad Sci USA 2012 ; 109 : 8699–8704. [CrossRef]
  10. Jego G, Hazoumé A, Seigneuric R, Garrido C. Targeting heat shock proteins in cancer. Cancer Lett 2010, 13 novembre (online).
  11. Didelot C, Garrido C. HSP90 mitochondriale : la cible à inactiver dans la thérapie anti-cancéreuse ? Med Sci (Paris) 2008 ; 24 : 363–364. [CrossRef] [EDP Sciences] [PubMed]
  12. Garrido C, Collura A, Berthenet K, et al. Mutation d’HSP110 dans les cancers colorectaux : le paradoxe du chaperon qui ne protège plus. Med Sci (Paris) 2012 ; 28 : 9–10. [CrossRef] [EDP Sciences]
  13. Baylot V, Andrieu C, Katsogiannou M, et al. OGX-427 inhibits tumor progression, enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death Dis 2011 ; 2 : e221. [CrossRef] [PubMed]
  14. Rexer H. First line therapy for local advanced or metastasized urothelial carcinoma: randomized double-blind phase II study to compare gemcitabin and cisplatin in combination with OGX-427 or placebo for advanced transitional cell carcinoma of the bladder (OGX-427 - AB 39/11 of the working group urological oncology. Urologe A 2011 ; 50 : 1617–1618. [CrossRef] [PubMed]
  15. Panigrahy D, Edin ML, Lee CR, et al. Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest 2012 ; 122 : 178–191. [CrossRef] [PubMed]